- Projects & figures
- News & Events
- Managing your project
- About ERC
Tamoxifen, a drug used in breast cancer treatment, may be repositioned to treat pancreatic cancer
Pancreatic cancer is the 4th leading cause of death by cancer in Europe. It has a very low survival rate with less than 1 per cent of sufferers surviving for 10 or more years. Over the last 40 years the survival rate has not significantly changed and finding an effective therapy has become a pressing challenge in cancer research. A team based at Imperial College London led by Armando Del Río Hernández, has now demonstrated that a well-known drug could be effective to fight this deadly and other forms of cancer, such as liver cancer.
CRISPR is a widely used molecular biology tool exploiting an immune process discovered in bacteria. Dr David Bikard studies CRISPR in bacterial cells, in conjunction with different DNA repair systems, to create even newer tools. He hopes to gain insight into bacterial genetics, and develop increasingly effective medical treatments.
The human brain is a remarkable organ, but how did it evolve to give us such unprecedented cognitive abilities? ERC grantee Pierre Vanderhaeghen and his team from ULB, VIB-KU Leuven turned to the genome for answers: a specific set of genes, found only in humans, could play a determinant role on the size of our brain. Published today in Cell, Vanderhaeghen's EU-funded research helps to unlock the secrets of human evolution.
Prof. Gregoire Courtine believes paralysed patients will be able to walk again. This belief has represented the focus of years of work aimed at regenerating the functions of the spinal cord after injury. Thanks to his ERC funding in both 2010 and 2015, Prof. Courtine and his team have been able to develop so-called “personalised neuroprosthetics” that have led immobile rats, and more recently monkeys, to overcome their paralysis.
Ole Kamstrup, MD., MSc., is a pensioner and lives north of Copenhagen in Denmark. He has been diagnosed with Parkinson's disease ten years ago. Since 2013, Mr Kamstrup has been in contact with Professor Deniz Kirik, a neuroscientist at Lund University in Sweden. Professor Kirik, who was awarded an ERC Starting Grant in 2009, develops new therapies for Parkinson’s disease, using viral vectors to deliver therapeutic genes to the brain. An ERC Proof of Concept grant enabled him to start carrying out a market evaluation and writing a business plan for the promising therapy.
Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."
By focusing on certain actions and reactions within the brain, an EU-funded project has advanced understanding of how Alzheimer’s Disease develops. This could potentially open the door to a new era of targeted treatments.
A crucial discovery of how the brain functions has been made by EU-funded researchers. ERC Advanced Grant holder Prof. Oscar Marin and his team have shown that brain's 'hardware' - using the computing metaphor - is in fact tuneable and can adapt to internal and external influences. The findings could help develop new therapies for neurological disorders such as epilepsy, which affects around 50 million people globally.
ERC grantee Marta Moita and her team use cutting-edge experimental procedures to investigate how rats and flies learn to appropriately respond to danger from other individuals. The results of her study may teach us a lot about our own brains, and shed light on diseases that impair social behaviour.
ERC grantee Professor Deniz Kirik's spin-off company will join forces with Skåne Regional Council in southern Sweden to build a specialised hospital and a state-of-the-art gene therapy centre, the parties announced on 8 October. The new facilities are expected to be operational by 2020. They will provide researchers unique opportunities for clinical trials, while patients will gain access to the latest treatment methods for Parkinson’s disease and other illnesses.
Dr Málnási-Csizmadia focuses on enzymes, proteins essential for body functions, and the largely unexplored intricate mechanisms underlying their activity. His recent findings could open the way to a ground-breaking development in pharmacology, especially in targeted cancer therapy.